Is BenevolentAI (OTC:BAIVF) “rebooting pharma in the AI era”?
Quite possibly, according to Deutsche Bank, which recently launched coverage on the London-headquartered company.
Deutsche analysts called BenevolentAI (OTC:BAIVF) “one of the few listed TechBio companies that is combining big data analytics with proprietary AI in order to mine an immense catalogue of scientific literature and a wealth of patient data for a deeper understanding of human health and disease”.
With more patent approvals on the way and a strong balance sheet, Benevolent AI has a “proven ability to uncover new targets for pharma partners; attractive balance of internal pipeline and partnerships; a well aligned management team and the ability to validate therapeutic candidates far more efficiently to shorten time lines between discovery and drug approval”.
Analysts highlighted that of the two clinical assets discovered through the BenevolentAI platform, one has received Food and Drug Administration approval and the other was dropped early after mixed data, making for a 50% hit rate on clinical-stage assets.
Added together and Deutsche sees the stock as a buy with a €2.7 price target against a €0.79 publication price.